Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodegenerative disorder.

Analysts have suggested that approval for AAD could swell sales of Rexulti by $500 million to $1 billion, a big step up for a drug which currently makes around $1.4 billion in annual sales.

That includes Rexulti, a drug from Japan’s Otsuka Pharmaceutical that is approved for treating Alzheimer’s agitation. Minter wrote that Axsome’s AXS-05 may have a more appealing safety ...